Rifaximin suspension mix granule formulation

Abstract

A dried rifaximin suspensoid pelletized granule, which is prepared by mixing rifaximin as the active component and medicinal auxiliary materials at the weight ratio of 1í†5í½35. The medicinal auxiliary materials mainly comprise the suspending agent and the flocculating agent at the weight ratio of 1í†0.05í½2. The suspending agent comprises two or three of microcrystal cellulose, methylcellulose, sodium methylol cellulose, hydroxypropyl methylcellulose, sodium alginate, gum arabic and pectine. The flocculating agent is one of citrate, tartrate, phosphate and aluminum chloride. Other auxiliary materials contain cane sugar, starch, food sweetening agent, preservative and flavoring and so on.

Description

technical field [0001] The invention relates to the field of medicines, in particular to a rifaximin dry suspension granule capable of treating intestinal diseases. Background technique [0002] Rifaximin is a new type of antibiotic widely used among rifamycin derivatives. It can be used to treat acute and chronic intestinal infections caused by Gram-positive bacteria and Gram-negative bacteria, and can be used as a therapeutic agent for hyperammonia. Auxiliary drugs. This drug has a broad antibacterial spectrum and has antibacterial effects on aerobic or anaerobic bacteria in the gastrointestinal tract. Its biggest feature is that it is neither absorbed by the intestinal tract nor purified by gastric juice, that is, this product is almost not absorbed systematically, and the drug concentration cannot be detected in the urine and tissues of patients after taking it, but is only excreted in its original form through the large intestine. Therefore, its toxic and side effects...

AI Technical Summary

Problems solved by technology

Chinese patent application No. 98106920 discloses a use of rifaximin, which uses rifaximin to treat diarrhea caused by cryptosporidiosis in patients with severe forms of immunosuppression, due to the adaptation of the invention However, most of the rifaximin used clinically is in the form of tablets, which are not easy to swallow, and are especially not suitable for the treatment of elderly or children with intestinal infection who have difficulty swallowing.